Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | TPMT | P51580 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.56 |
| ▸ | PDE4A | P27815 | 3/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643490 | 1.00 | LMNA (0.75) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL9149352 | 0.87 | LMNA (0.60) | LMNAMAPK1HTTRAB9AJAK2 | |
| SCHEMBL5582160 | 0.87 | LMNA (0.60) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL503994 | 0.86 | HTT (1.00) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL31493230 | 0.86 | HTT (1.00) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL5149280 | 0.86 | LMNA (0.69) | LMNAMAPK1HTTRAB9ACA12 | |
| SCHEMBL14156962 | 0.85 | LMNA (0.63) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL2040708 | 0.84 | CA12 (0.72) | LMNAMAPK1HTTRAB9ACA12 | |
| SCHEMBL21561215 | 0.83 | LMNA (0.60) | LMNAMAPK1HTTRAB9AKDM4E | |
| SCHEMBL4600237 | 0.83 | LMNA (0.60) | LMNAMAPK1HTTRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | LMNA 1626/4885MAPK1 2357/4885HTT 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.